title: Polymer--drug conjugates as nano-sized medicines.
abstract: Polymer Therapeutics have enormously evolved in the past decades. Several polymeric drugs as well as polymer-protein conjugates have been in the market since the 90s, but although polymer-drug conjugates are already in clinical trials they still need to reach this final goal. There are four main convergent strategies to move this platform technology further. First, exploitation of new molecular targets in cancer therapy and design of polymer-drug conjugates as treatments for other diseases. Second, the development of combination therapy. Third, attempts to improve polymer chemistry, including the use of new well-defined architectures and the optimization of the advanced characterization techniques essential to transform a promising conjugate into a candidate for clinical evaluation. Finally, increased understanding of polymer conjugate features that govern clinical risk-benefit is leading to an appreciation of clinical biomarkers that will open new possibilities for personalized therapy.
authors: Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av. Autopista del Saler 16, E-46012 Valencia, Spain.
authors: Fabiana
authors: F
authors: Canal
authors: Joaquin
authors: J
authors: Sanchis
authors: María J
authors: MJ
authors: Vicent
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D050997:Nanomedicine / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011108:Polymers / Q000737:chemistry* / Q000627:therapeutic use*; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D004364:Pharmaceutical Preparations; D011108:Polymers